STOCK TITAN

Alnylam Pharmaceuticals Inc reported $3.7B in revenue and $313.7M in net income for fiscal 2025. See the full ALNY financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

Alnylam (ALNY) will present company overviews at two investor conferences in September 2026, both with live webcasts.

(Neutral)
(Neutral)
Tags
conferences
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:

  • Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8, 2026, at 8:45 AM ET in Everett, Massachusetts
  • Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026, at 10:00 AM ET in New York City

A live audio webcast of each presentation will be available on the Investors section of the Company’s website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit www.alnylam.com or follow Alnylam on X, LinkedIn, Facebook, Instagram, or YouTube.

Alnylam Pharmaceuticals, Inc.

Bo Piela
(Media)
508-308-9783

Josh Brodsky
(Investors)
617-551-8276

Source: Alnylam Pharmaceuticals, Inc.